Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS
Ovarian Hyperstimulation Syndrome
About this trial
This is an interventional prevention trial for Ovarian Hyperstimulation Syndrome
Eligibility Criteria
Inclusion Criteria:
- infertile women
- age 20-40
- at high risk for OHSS
Exclusion Criteria:
- refuse to participate
Sites / Locations
- Alazahr University
- Assisted Reproduction Unit International Islamic Centre for Population Studies and Research, Al-Azhar University
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Coasting group
Antagonist group
Including 150 patients who will undergo withholding gonadotropin administration for at least 24 hours before triggering ovulation with hCG. GnRH agonist will be continued daily till the day of triggering. E2 will be measured daily until the concentration falls to ≤ 3000 pg/ml, then 5000 IU of hCG will be given.
Including 150 patients who will receive GnRH antagonist (subcutaneous injection Cetrorelix acetate 0.25 mg (Cetrotide, Serono, UK)) daily until the day of hCG administration. GnRH agonist will be discontinued at the start of antagonist administration. E2 will be measured daily until the concentration falls to ≤ 3000 pg/ml and TVS revealed that follicles diameter is ≥ 18 mm, then 5000 IU of hCG will be given.